ZUG, Switzerland and CAMBRIDGE, Mass. and SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced that Health Canada has approved the companies\u2019 Clinical Trial Application (CTA) for VCTX210, an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). Initiation of patient enrollment is expected by year-end.<\/p>\n

\u201cWith the approval of our CTA, we are excited to bring a first-in-class CRISPR-edited cell therapy for the treatment of type 1 diabetes to the clinic, an important milestone in enabling a whole new class of gene-edited stem cell-derived medicines,\u201d said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. \u201cThe combination of ViaCyte\u2019s leading stem cell capabilities and CRISPR Therapeutics\u2019 pre-eminent gene-editing platform has the potential to meaningfully impact the lives of patients living with type 1 diabetes.\u201d<\/p>\n

http:\/\/www.crisprtx.com\/about-us\/press-releases-and-presentations\/crispr-therapeutics-and-viacyte-inc-to-start-clinical-trial-of-the-first-gene-edited-cell-replacement-therapy-for-treatment-of-type-1-diabetes<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

ZUG, Switzerland and CAMBRIDGE, Mass. and SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced that Health Canada […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[24],"tags":[],"_links":{"self":[{"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/posts\/642"}],"collection":[{"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/comments?post=642"}],"version-history":[{"count":1,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/posts\/642\/revisions"}],"predecessor-version":[{"id":643,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/posts\/642\/revisions\/643"}],"wp:attachment":[{"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/media?parent=642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/categories?post=642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/tags?post=642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}